Angela HUTTNER
Quick facts
Phase 3 pipeline
- Ceftazidime± avibactam with fosfomycin · Infectious Disease
Ceftazidime-avibactam inhibits bacterial cell wall synthesis while avibactam protects against beta-lactamase degradation, and fosfomycin provides additional cell wall disruption through a distinct mechanism.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: